Market Place
Sourcing Support
ARS Pharma Files for neffy® Approval in China, Japan & Australia
12 Dec 2024 //
GLOBENEWSWIRE
ARS Pharma Reports Q3 2024 Financial Results & Business Updates
13 Nov 2024 //
GLOBENEWSWIRE
ALK licenses rights to neffy for emergency treatment of Anaphylaxis
09 Nov 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals to Host Q3 2024 Call & Present at Conferences
06 Nov 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Showcases Data At ACAAI Annual Meeting
24 Oct 2024 //
GLOBENEWSWIRE
BlinkRx Offers Neffy, The First Needle-Free Epinephrine Treatment
07 Oct 2024 //
BUSINESSWIRE
ARS Pharmaceuticals` Neffy Poised To Disrupt Epinephrine Market
01 Oct 2024 //
EXPRESSPHARMA
Renaissance Lakewood Backs ARS Pharma’s Nasal Spray For Allergies
30 Sep 2024 //
PRESS RELEASE
GoodRx Announces Lowest Cash Price For Neffy
26 Sep 2024 //
BUSINESSWIRE
ARS Pharma Announces US Availability Of Neffy Nasal Spray
23 Sep 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals To Participate In Cantor Conference
10 Sep 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Submits sNDA For neffy 1 mg Dose
09 Sep 2024 //
GLOBENEWSWIRE
ARS Launches Pre-Ordering For Needle-Free neffy®
04 Sep 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals`s Eurneffy (epinephrine) Receives Approval in Europe
22 Aug 2024 //
EMA
ARS Pharma Launches Epinephrine Nasal Spray With High Potential
21 Aug 2024 //
FIERCE PHARMA
ARS Pharma`s Neffy® Approved As First Needle-Free Anaphylaxis Treatment
10 Aug 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals To Participate In Wedbush PacGrow Healthcare Conference
07 Aug 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
ARS Pharma`s EURneffy Nasal Spray Recommended by CHMP for Anaphylaxis
28 Jun 2024 //
GLOBENEWSWIRE
ARS Highlights neffy Regulatory Progress, Q1 2024 Financials
09 May 2024 //
GLOBENEWSWIRE
ARS Submits neffy® Response To EMA, Partners With CSL Seqirus
30 Apr 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy®
03 Apr 2024 //
GLOBENEWSWIRE
ARS gears up for neffy US approval
22 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
ARS Provides Business Update and Reports Q4 and FY3 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Reviews Commercial Opportunity at neffy Investor Day
07 Mar 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals to Participate in the Leerink Partners Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals announces neffy® meets primary endpoints
26 Feb 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
22 Feb 2024 //
GLOBENEWSWIRE
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy
20 Feb 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy
05 Feb 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy
09 Nov 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
ARS Pharma Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy
06 Oct 2023 //
GLOBENEWSWIRE
Single and Repeat Dose Clinical Study of neffy Published
03 Oct 2023 //
GLOBENEWSWIRE
FDA Issues CRL for neffy NDA with Request for Additional Study
20 Sep 2023 //
GLOBENEWSWIRE
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
10 Aug 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Highlights Progress and Reports 1Q 2023 FYR Results
15 May 2023 //
GLOBENEWSWIRE
FDA adcomm votes in favor of ARS Pharmaceuticals` EpiPen alternative
12 May 2023 //
ENDPTS
ARS Pharma Announces Briefing Documents for FDA Advisory Committee on neffy
09 May 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy
28 Mar 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Highlights Progress and 4Q & 2022 FYR
23 Mar 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy
23 Feb 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy
22 Feb 2023 //
GLOBENEWSWIRE
ARS to Participate in SVB Securities Virtual Global Biopharma Conference 2023
09 Feb 2023 //
GLOBENEWSWIRE
FDA Accepted Intranasal Epinephrine NDA of Ars Pharmaceuticals
09 Dec 2022 //
BIONJ
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy
10 Nov 2022 //
GLOBENEWSWIRE
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
08 Nov 2022 //
BIOSPACE
FDA accepts ARS’ filing for nasal spray EpiPen rival for review
25 Oct 2022 //
FIERCEPHARMA
ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy
21 Oct 2022 //
BUSINESSWIRE
As Silverback admits defeat, ARS troops forward to fund commercialization
27 Jul 2022 //
FIERCEPHARMA
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
21 Jul 2022 //
BUSINESSWIRE
ARS Pharma Appoints Eric Karas as CCO and Kathleen Scott as CFO
05 Apr 2022 //
BUSINESSWIRE
ARS Pharmaceuticals Expands Executive Leadership Team
09 Feb 2022 //
PRNEWSWIRE
Meet Neffy, the friendly epinephrine nasal spray from ARS Pharma awaiting FDA approval
07 Sep 2021 //
FIERCE PHARMA
ARS Pharma awaits FDA approval for its epinephrine nasal spray, Neffy
03 Sep 2021 //
FIERCEPHARMA
ARS Pharmaceuticals Raises $55 Million in Series D Funding
31 Aug 2021 //
PRNEWSWIRE
SR One leads $55M round; Sanofi pulls website over accuracy concerns
31 Aug 2021 //
ENDPTS
ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)
14 Jul 2020 //
PRNEWSWIRE
ARS Pharmaceuticals Announces New Patent on ARS-1 (epinephrine nasal spray)
13 Jul 2020 //
PRNEWSWIRE
Neurelis Announces That Intravail® Licensee, ARS Pharma` Intranasal Epinephrine
04 May 2020 //
PRNEWSWIRE
